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Figure 1. Change in pain scores on the 50-foot Walk Test from baseline
to week 26 ITT population.
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Purpose: Within the last few decades the concept of disease modifying
drugs (DMOAD) have been explored as alternative therapeutic treatment
modalities for osteoarthritis (OA). From the results of previous in vitro
and animal model studies, we have proposed that the spectrum of phar-
macological activities exhibited by Sodium Pentosan Polysulfate (NaPPS)
would qualify it as a DMOAD. However human clinical evidence to support
this proposition was a few. To assess the efﬁcacy, safety, and patient
satisfaction with a series of subcutaneous injections of NaPPS in the
patients who reported knee joint OA-associated pain, loss of ROM, and
disability that interfered with daily life and work
Methods: NaPPS is a semi-synthetic drug manufactured from beech-
wood hemicellulose by sulfate esteriﬁcation of the xylopyranose hydroxyl
groups. It has an average mean molecular weight of 5700Da. NaPPS in
this study was manufactured and supplied in injectable vials (100mg/ml)
by bene-Arzneimittel GmbH, Munich, Germany.
The open trial was undertaken with 20 patients with knee OA. Patients
were clinically assessed at entry and 1, 2, 3, 4, 8, 12, 16, 24 and 52 weeks
with physical examination and VAS for stiffness, pain at rest or walking,
ROM exercises, walking up and down stairs. A modiﬁed WOMAC OA
index was used for lifestyle parameters. Degradation of type II Collagen
(C2C) in Blood was measured with an ELISA kit, in accordance with the
manufacturer’s instructions.
Before the treatment, 2 weeks of NSAIDs washout period was made,
if necessary. Treatment consisted of 6 weekly subcutaneous injections
(sc) of NaPPS (2mg/kg). The protocol and written informed consent for
studies involving human subjects were approved by the review board in
our university. The statistical signiﬁcance, compared with the value at
entry, was determined by one way ANOVA and Dunnett’s method.
Results: The attribution of patients was as following: The average year
was 63 years old, All cases were female, were included in grade 1 to
2 according the classiﬁcation of Kellgren and Lawrence. The average of
WOMAC score at the ﬁrst visit was 37.0. All cases could be followed for
one year.
The dose of this PPS effected the blood coagulation test, but the value
in the study was within safety area. A tiny abnormal ﬁnding is noted in
serum chemistry: ie: serum triglyceride 1 hr after injection., but it was
reduced quickly in followed up period.
The hydroarthroses were reduced quickly in all cases. ROM of the knee
joint was improved. The clinical assessments, i.e. knee ﬂexion, pain at
walking, pain just after climb up and down stairs, pain just after ROM
exercise were improved signiﬁcantly. The concentration of C2C in Blood
were decreased signiﬁcantly. The clinical effect was continued for almost
one year.
The improvement of X ray ﬁndings could not detected.
In the previous vitro study, PPS reduced cartilage degradation by directly
and indirectly affecting these inﬂammatory mediators such as MMP-3.
PPS increased both the synthesis and the molecular weight of hyaluro-
nan. PPS had anti-inﬂamatory function. As the results of C2C in Blood,
quickly reducion of hydroarthroses and improvement of the knee joint
R.O.M., our result was compatible to the above vitro study
Conclusions: The availability, safety of NaPPS for knee osteo-arthlitis
patients and satisfaction level of patients was studied.
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Purpose: Our previous studies showed that the essential oil from the
leaves of Juniperus oxycedrus has potential value as a source of new
compounds capable of targeting the NF-úB signaling pathway in OA
chondrocytes. Upon fractionation, a fraction designated F3 proved to be
effective in reducing Il-1-induced NF-úB activation and NO production.
Since that fraction contains predominantly a racemic mixture of (+)-
and (−)-a-pinene, we compared its ability to inhibit those Il-1-induced
responses with those of pure commercial racemic a-pinene, (+)- and
(−)-a-pinene enantiomers, as well as with that of turpentine oil, another
natural source of racemic a-pinene. b-pinene was also tested.
Methods: The essential oil from Juniperus oxycedrus leaves was frac-
tionated by liquid chromatography and analyzed by gas chromatogra-
phy and gas chromatography-mass spectroscopy . a-pinene constitutes
approximately 92% of F3. Human chondrocytes were isolated from the
femoral condyles of multi-organ donors and used to evaluate the ability
of F3, turpentine oil and pure pinene isomers to inhibit Il-1-induced
NO production. The human chondrocytic cell line, C-28/I2, was used to
evaluate NF-úB activation. Both cell culture types were treated for 30min
with the essential oils or fraction, in two different dilutions, followed by
treatment with Il-1b (30 ng/ml) for 30min or 18 h to evaluate, respectively,
the cytoplasmic levels of IúB-a by western blot, or NO production by
the Griess reaction. To determine whether the test compounds have any
direct effect on iNOS enzyme activity, NO production was evaluated in
cell cultures pretreated with Il-1, 30 ng/ml, to induce the expression of the
enzyme before the addition of the test compounds. The MTT reduction
assay was used to rule out cytotoxic effects.
Table 1: Effect of pretreatment with natural and synthetic pinene isomers on Il-1-induced NO
production
NO production induced by Il-1b 30 ng/ml
Test compound dilution 1:7500 Test compound dilution 1:5000
No pretreatment 100.0±6.0%
Commercial racemic a-pinene 58.5±7.5% 40.6±3.4%
(+)-a-pinene 56.2±10.8% 30.1±2.9%
(−)-a-pinene 63.4±7.8% 57.3±6.0%
b-pinene 82.9±13.7% 76.7±14.7%
F3 51.4±7.3% 11.3±0.4%
Turpentine oil 71.8±3.5% 51.2±1.9%
Results: As shown in the table, F3, containing racemic a-pinene from
natural origin, is the most effective in reducing Il-1-induced NO produc-
tion (11.3%±0.4). When added to the chondrocyte cultures 18 h after
addition of Il-1, F3 also reduced NO production, although with a lower
magnitude than when added to the cell cultures before Il-1. Among the
pure compounds, (+)-a-pinene was the most effective in reducing Il-1-
induced NO production (30.1%±2.9), either when added before or after
Il-1. b-Pinene was only slightly active. F3 and (+)-a-pinene were also the
most effective in preventing Il-1-induced IúB-a degradation.
Conclusions: (+)-a-Pinene is more active than its (−) enantiomer. Since
F3 achieved a greater inhibition of both NF-úB activation and NO
production than the commercial racemic a-pinene or the (+)-a-pinene
enantiomer, it is possible that other minor components of that fraction
will also be active. The results obtained also indicate that a-pinene acts
